(5-chloro-6-methylpyridin-3-yl)methanol | 917835-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-chloro-6-methylpyridin-3-yl)methanol
• 英文别名: (5-chloro-6-methyl-3-pyridinyl)methanol；5-Chloro-6-methylpyridine-3-methanol
• CAS: 917835-64-4
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: YJNHSDCFCPDBBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-chloro-6-methylpyridin-3-yl)methanol 在 吡啶 、 三氧化硫吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 以88%的产率得到5-氯-6-甲基-3-吡啶羧醛
  参考文献：
  名称：

  COMPOUNDS

  摘要：

  公式(I)的化合物或其药用可接受的盐或N-氧化物，(相对化学显示)包含它们的药物组合物，它们在治疗中的用途特别是针对结核病，以及制备它们的方法被描述。

  公开号：

  US20090306089A1

文献信息

• [EN] NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO<br/>[FR] NOUVEAUX COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS CORRESPONDANTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010149684A1

  公开（公告）日：2010-12-29

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明公开了具有结构(I)的新化合物，其在患者中治疗各种与代谢相关的病症具有实用性：其中R1、R2、R3、n、p、q和Ar如本文所定义，包括立体异构体、溶剂合物和药学上可接受的盐。还公开了包含本发明化合物的药物组合物，以及关于其在有需要的患者中使用的方法。
• 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS
  申请人：Castro Pichel Julia

  公开号：US20130203802A1

  公开（公告）日：2013-08-08

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR 5 ; or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and C 1-2 alkyl; R 2 is selected from H, C 1-2 alkyl, OH, —CH 2 OH and C 1-2 alkoxy; Each R 3 is independently selected from OH, C 1-3 alkyl, F, Cl, Br, NH 2 , and C 1-3 alkoxy; R 4 is selected from C 1-3 alkyl and haloC 1-3 alkyl; R 5 is selected from H, C 1-3 alkyl and haloC 1-3 alkyl; R 6 and R 7 are either i) each independently selected from H, C 1-3 alkyl and C 1-3 alkoxy; or ii) R 6 and R 7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and R A is selected from H and C 1-3 alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  公式（I）的化合物或其药用盐：其中：Het是5至10成员的杂环芳香环；X为N且Y为CR5；或X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H、C1-2烷基、OH、—CH2OH和C1-2烷氧基中选择；每个R3独立选择自OH、C1-3烷基、F、Cl、Br、NH2和C1-3烷氧基；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H、C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立选择自H、C1-3烷基和C1-3烷氧基；要么ii）R6和R7与它们附着的环一起形成9成员双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病的治疗中，并提供了这类化合物的制备方法。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。
• Compounds
  申请人：Glaxo Group Limited

  公开号：US08097628B2

  公开（公告）日：2012-01-17

  Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: (relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them are described.

  本文描述了公式(I)的化合物或其药学上可接受的盐或N-氧化物：（相对化学式显示），包括它们的药物组成物，它们在治疗结核病方面的用途，以及制备它们的方法。
• NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
  申请人：Kiyoto Taro

  公开号：US20100168418A1

  公开（公告）日：2010-07-01

  A nitrogen-containing heterocyclic compound represented by the general formula: wherein the dashed line represents a single bond or a double bond; R 1 , R 2 , R 3 , R 4 and R 5 independently represent a hydrogen atom, halogen atom, a lower alkyl, aryl, lower alkoxy or monocyclic heterocyclic group which may be substituted or the like; R 6 represents a lower alkyl, aryl, monocyclic heterocyclic, bicyclic heterocyclic or tricyclic heterocyclic group which may be substituted; X 1 represents a lower alkylene group or the like; X 2 represents a lower alkylene, lower alkenylene or lower alkynylene group which may be substituted; X 3 represents an oxygen atom, sulfur atom, a sulfinyl group, sulfonyl group or the like; Y 1 represents a bivalent cyclic group, containing a nitrogen, which may be substituted or the like; and Z 1 represents a nitrogen atom, a carbon atom which may be substituted or the like, or a salt thereof. The compound or salt has a potent antibacterial activity and a high safety, and is therefore useful as an excellent antibacterial agent.

  一种含氮杂环化合物，通式如下：其中虚线代表单键或双键；R1、R2、R3、R4和R5分别独立地代表氢原子、卤素原子、较低的烷基、芳基、较低的烷氧基或可以被取代的单环杂环基等；R6代表较低的烷基、芳基、单环杂环、双环杂环或三环杂环基，可以被取代；X1代表较低的烷基亚基或类似物；X2代表可以被取代的较低烷基、较低烯基或较低炔基亚基；X3代表氧原子、硫原子、亚砜基、磺酰基或类似物；Y1代表含有氮的二价环状基团，可以被取代或类似物；Z1代表氮原子、可以被取代的碳原子或类似物，或其盐。该化合物或盐具有强效的抗菌活性和高度的安全性，因此可用作优良的抗菌剂。